Literature DB >> 7480549

Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects.

J C Fleishaker1, P D Garzone, J H Chambers, K Sirocco, H Weingartner.   

Abstract

Single doses of alprazolam (0, 0.5, 1.5 mg) or adinazolam mesylate sustained release tablets (SR) (0, 15, 45 mg) were administered to separate groups of 12 healthy men in a crossover design. Psychomotor performance was assessed by digit symbol substitution (DSST), and memory was assessed using a test battery which reflects various aspects of memory, including attention/working memory, explicit memory (recall of categorically related words), semantic memory (fragmented picture recognition, generation of category exemplars), and implicit memory (time saved in resolving fragmented pictures on the second exposure). Maximal psychomotor performance and memory decrements for the highest active doses were significantly different from placebo for all tasks at some time after dosing. The maximum decrement in DSST was not significantly different between drugs at the high dose (P = 0.288). Maximum attention/working memory decrements were significantly different between the high doses of the active compounds (P = 0.031), and the difference in maximum category recall decrement was marginally significant (P = 0.067). Access to knowledge memory was not significantly altered by these drugs; these results are similar to those obtained for other benzodiazepines. Both drugs exhibited slight effects on implicit memory. The results suggest that the sedative and memory effects of these triazolobenzodiazepines may not be closely related and suggest that adinazolam has a somewhat different spectrum of cognitive effects relative to alprazolam.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7480549     DOI: 10.1007/bf02246190

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

1.  A comparison of the single-dose effects of alprazolam, buspirone, and placebo upon memory function.

Authors:  J G Barbee; F W Black; C E Kehoe; A A Todorov
Journal:  J Clin Psychopharmacol       Date:  1991-12       Impact factor: 3.153

2.  Adinazolam pharmacokinetics and behavioral effects following administration of 20-60 mg oral doses of its mesylate salt in healthy volunteers.

Authors:  J C Fleishaker; J P Phillips
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Diazepam induces a dissociation between explicit and implicit memory.

Authors:  J M Danion; M A Zimmermann; D Willard-Schroeder; D Grangé; L Singer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Relative amnesic actions of diazepam, flunitrazepam and lorazepam in man.

Authors:  K A George; J W Dundee
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

5.  Diazepam and memory: evidence for spared memory function.

Authors:  J C Fang; J V Hinrichs; M M Ghoneim
Journal:  Pharmacol Biochem Behav       Date:  1987-11       Impact factor: 3.533

6.  Psychomotor and memory effects of two adinazolam formulations assessed by a computerized neuropsychological test battery.

Authors:  J C Fleishaker; T A Sisson; J J Sramek; J Conrad; A E Veroff; N R Cutler
Journal:  J Clin Pharmacol       Date:  1993-05       Impact factor: 3.126

7.  Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo.

Authors:  D J Greenblatt; J S Harmatz; C Dorsey; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1988-09       Impact factor: 6.875

8.  Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.

Authors:  C S Carter; J Fawcett; M Hertzman; L A Papp; W Jones; W M Patterson; R P Swinson; C C Weise; R J Maddock; A Q Denahan
Journal:  J Clin Psychiatry       Date:  1995-05       Impact factor: 4.384

9.  Pharmacokinetic and pharmacodynamic comparison of immediate-release and sustained-release adinazolam mesylate tablets after single- and multiple-dose administration.

Authors:  J C Fleishaker; C E Wright
Journal:  Pharm Res       Date:  1992-04       Impact factor: 4.200

10.  Multiple-dose pharmacokinetics and pharmacodynamics of adinazolam in elderly subjects.

Authors:  J C Fleishaker; J P Phillips; T C Smith; R B Smith
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

View more
  3 in total

1.  Prediction of modified release pharmacokinetics and pharmacodynamics from in vitro, immediate release, and intravenous data.

Authors:  Viera Lukacova; Walter S Woltosz; Michael B Bolger
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

2.  Midazolam does not inhibit association formation, just its storage and strengthening.

Authors:  Lynne M Reder; Iain Proctor; John R Anderson; Ferenc Gyulai; Joseph J Quinlan; Joyce M Oates
Journal:  Psychopharmacology (Berl)       Date:  2006-08-03       Impact factor: 4.530

3.  Impact of alprazolam in allostatic load and neurocognition of patients with anxiety disorders and chronic stress (GEMA): observational study protocol.

Authors:  Carlos A Soria; Carolina Remedi; Daniel A Núñez; Luciana D'Alessio; Emilio J A Roldán
Journal:  BMJ Open       Date:  2015-07-14       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.